Pfizer Inc. (NYSE:PFE) Shares Acquired by Van Strum & Towne Inc.

Van Strum & Towne Inc. boosted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 22.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 85,584 shares of the biopharmaceutical company's stock after purchasing an additional 15,900 shares during the period. Van Strum & Towne Inc.'s holdings in Pfizer were worth $2,169,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the business. HighPoint Advisor Group LLC lifted its stake in Pfizer by 13.4% during the 1st quarter. HighPoint Advisor Group LLC now owns 229,367 shares of the biopharmaceutical company's stock valued at $5,457,000 after acquiring an additional 27,026 shares during the period. Edgemoor Investment Advisors Inc. lifted its stake in shares of Pfizer by 1,040.9% in the 1st quarter. Edgemoor Investment Advisors Inc. now owns 213,573 shares of the biopharmaceutical company's stock valued at $5,412,000 after purchasing an additional 194,853 shares during the period. Wealth Dimensions Group Ltd. lifted its stake in shares of Pfizer by 7.0% in the 1st quarter. Wealth Dimensions Group Ltd. now owns 29,783 shares of the biopharmaceutical company's stock valued at $755,000 after purchasing an additional 1,938 shares during the period. 4WEALTH Advisors Inc. increased its holdings in Pfizer by 25.9% in the 1st quarter. 4WEALTH Advisors Inc. now owns 13,490 shares of the biopharmaceutical company's stock worth $342,000 after acquiring an additional 2,779 shares in the last quarter. Finally, Miller Financial Services LLC increased its holdings in Pfizer by 7.0% in the 1st quarter. Miller Financial Services LLC now owns 17,363 shares of the biopharmaceutical company's stock worth $440,000 after acquiring an additional 1,133 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently commented on PFE shares. Bank of America boosted their price target on shares of Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Leerink Partners cut their price target on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a report on Wednesday, April 30th. Redburn Atlantic cut their price target on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a report on Wednesday, April 30th. Wolfe Research boosted their price target on shares of Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a report on Wednesday, April 30th. Finally, UBS Group upped their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $28.55.

Pfizer Trading Down 0.2%

NYSE PFE traded down $0.05 during trading hours on Thursday, reaching $25.32. The company had a trading volume of 12,267,735 shares, compared to its average volume of 45,424,172. The stock has a 50-day moving average of $24.20 and a 200 day moving average of $24.71. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $143.93 billion, a P/E ratio of 18.34, a price-to-earnings-growth ratio of 0.92 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. During the same quarter in the prior year, the company posted $0.82 earnings per share. Pfizer's revenue for the quarter was down 7.8% compared to the same quarter last year. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.79%. Pfizer's dividend payout ratio is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.